Rapid evolution of pan-β-lactam resistance in Enterobacterales co-producing KPC and NDM: insights from global genomic analysis after the COVID-19 pandemic
Fábio P. Sellera, Nilton Lincopán, Danny Fuentes‐Castillo, Eliana Guedes Stehling, João Pedro Rueda Furlan
Abstract
Enterobacterales co-producing Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM) enzymes are rapidly emerging worldwide.1–5 In some countries, this emergence has been linked to the empirical use of antimicrobials for potential bacterial infections associated with COVID-19 during the pandemic period.1,3–6 Concurrently, Latin American and Caribbean countries reported the occurrence and rapid dissemination of carbapenemase combinations, predominantly associated with KPC and NDM, to PAHO/WHO, triggering the issuance of an epidemiological alert.
Topics & Concepts
AztreonamKlebsiella pneumoniaeScopusCeftazidime/avibactamPandemicMicrobiologyBiologyVirologyAntibiotic resistanceMedicineCoronavirus disease 2019 (COVID-19)Escherichia coliMEDLINEImipenemAntibioticsGeneticsDiseaseInfectious disease (medical specialty)PathologyBiochemistryGeneAntibiotic Resistance in BacteriaAntibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy